The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Influence of radiation field on safety and efficacy for stage II/III esophageal cancer treated with definitive chemoradiotherapy: An exploratory analysis of JCOG0909.
 
Azusa Komori
No Relationships to Disclose
 
Shuichi Hironaka
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - AstraZeneca; MSD K.K
 
Ryunosuke Machida
No Relationships to Disclose
 
Yoshinori Ito
No Relationships to Disclose
 
HIROYA TAKEUCHI
No Relationships to Disclose
 
Gakuto Ogawa
No Relationships to Disclose
 
Ken Kato
Consulting or Advisory Role - BeiGene; MSD; Oncolys BioPharma; Oncolys BioPharma; Ono Pharmaceutical
Research Funding - Beigene (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst)
 
Masakatsu Onozawa
No Relationships to Disclose
 
Keiko Minashi
Research Funding - MSD (Inst); Ono Pharmaceutical (Inst)
 
Tomonori Yano
Honoraria - AstraZeneca; Eisai; Olympus
 
Kenichi Nakamura
Honoraria - Eisai; Merck Serono; Nihonkayaku; Taiho Pharmaceutical
 
Takahiro Tsushima
Honoraria - Chugai Pharma; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
 
Hiroki Hara
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Chugai Pharma; Merck Serono; MSD; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb-Ono Pharmaceutical (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Incyte (Inst); Lilly (Inst); LSK BioPharma (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Isao Nozaki
No Relationships to Disclose
 
Takashi Ura
No Relationships to Disclose
 
Keisho Chin
No Relationships to Disclose
 
Haruhiko Fukuda
Honoraria - Chugai Pharma; Taiho Pharmaceutical
 
Yuko Kitagawa
Honoraria - Asahi Kasei; Chugai Pharma; Ethicon; Nippon Kayaku; Olympus; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Ajinomoto (Inst); Asahi Kasei (Inst); Astellas Pharma (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); CSL Behring (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); EA Pharma (Inst); GlaxoSmithKline (Inst); Kaken Pharmaceutical (Inst); Kowa (Inst); Kureha (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Medicon (Inst); Medtronic (Inst); Merck Serono (Inst); Nippon Kayaku (Inst); Novartis (Inst); Otsuka (Inst); Otsuka (Inst); Pfizer (Inst); Sanofi (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Taisho Toyama Pharma (Inst); Takeda (Inst); Teijin Pharma (Inst); Tsumura & Co. (Inst); Yakult Honsha (Inst)